In combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic ESCC, whose tumors express PD-L1 (≥1).The structure of tislelizumab has been modified to maximally inhibit the binding of PD-1 to programmed death ligand 1 (PD-L1). The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.